Celadon Pharmaceuticals

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and supply of breakthrough cannabis-based medicines. Founded in 2018 after cannabis was legalised for medicinal purposes, Celadon was one of the first companies to receive Home Office and MHRA licences to cultivate and produce high-THC medicines. In March 2022, Celadon listed on the AIM market of the London Stock Exchange – a huge milestone in the industry and the first since GW Pharma (who were acquired for $7bn by Jazz in 2021). The Company has a clear mission: to improve quality of life for patients most in need through breakthrough cannabis-based medicines. The primary focus is addressing the 8 million chronic pain sufferers in the UK, who currently have little alternative to opioids. Celadon has a sq ft facility in the UK, comprising a large indoor hydroponic cultivation area, proprietary extraction and GMP standard API manufacturing, and an R&D and testing laboratory. It has been estimated by Canaccord that it would cost a new market entrant over £60m and 2-3 years minimum to replicated what Celadon has built in the UK. The Company's subsidiary, LVL Health, owns an MHRA conditionally approved clinical trial using cannabis-based medicines to treat chronic pain in the UK. The initial study is already live and interested patients can learn more here: Moreover, Celadon has a 20% stake in Kingdom Therapeutics, an early-stage biopharma developed a licenced cannabinoid medicine for children with Autism Spectrum Disorder. This forms part of Celadon’s ‘Breakthrough R&D’ programme, which aims to develop novel IP (molecules, delivery technology) and the future of cannabis-based medicines. Learn more about Celadon here: